ExlService
EXLS
35.51
+0.10
+0.28%
ExlService
US · EXLS
#2041 by market cap
Listed 1970
35.51
+0.10
+0.28%
Live - 5344 symbols - heartbeat 462s ago
· 2026-10-07 20:02
After-hours
35.06
-1.27%
- Market cap
- 5.38B
- P/E (TTM)i
- 22.47
- P/Bi
- 6.21
- EPSi
- 1.54
- Div yieldi
- 0.00%
- 52W posi
- 56%
Reader sentiment
Are you bullish or bearish on EXLS?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 7.54, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +13.56% YoY
Margins
- Gross margin
- 38.37%
- Operating margin
- 15.03%
- Net margin
- 12.02%
Key ratios & quality
- Enterprise valuei
- 5.37B
- PEG ratioi
- 1.09
- Altman Z-Scorei
- 7.54
PEG uses trailing P/E against the 3-year net income growth rate (20.64%/yr) since forward earnings estimates aren't available here, so this is not a "forward PEG." Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 883.11M | 991.35M | 958.43M | 1.12B | 1.41B | 1.63B | 1.84B | 2.09B |
| Gross profit | 298.26M | 335.86M | 334.50M | 431.36M | 515.45M | 607.77M | 691.01M | 801.08M |
| Selling & admin expenses | 179.81M | 198.75M | 174.01M | 226.35M | 267.01M | 318.52M | 372.17M | 428.24M |
| Research & development | -- | -- | -- | -- | -- | -- | -- | -- |
| Operating profit | 69.88M | 85.12M | 110.02M | 155.88M | 192.16M | 238.76M | 263.62M | 313.75M |
| Pretax profit | 60.37M | 83.10M | 115.33M | 146.56M | 190.10M | 237.94M | 261.35M | 315.05M |
| Tax | 3.40M | 15.17M | 25.63M | 31.85M | 47.57M | 53.54M | 62.94M | 63.73M |
| Net profit | 56.73M | 67.66M | 89.48M | 114.76M | 142.97M | 184.56M | 198.30M | 251.02M |
| Basic EPS | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 2 |
| Diluted EPS | 0.32 | 0.39 | 0.52 | 0.67 | 0.85 | 1.10 | 1.21 | 1.54 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 501.02M | 514.46M | 529.59M | 542.62M | 570.35M | 594.76M |
| Gross profit | 193.31M | 194.19M | 203.94M | 209.64M | 222.08M | 225.96M |
| Selling & admin expenses | 101.34M | 99.00M | 112.63M | 115.27M | 116.25M | 124.06M |
| Research & development | -- | -- | -- | -- | -- | -- |
| Operating profit | 78.42M | 81.14M | 76.17M | 78.02M | 91.83M | 87.30M |
| Pretax profit | 80.17M | 84.74M | 74.70M | 75.45M | 91.40M | 83.97M |
| Tax | 13.50M | 18.55M | 16.46M | 15.23M | 24.32M | 19.43M |
| Net profit | 66.56M | 66.05M | 58.16M | 60.25M | 67.08M | 64.51M |
| Basic EPS | 0 | 0 | 0 | 0 | 0 | 0 |
| Diluted EPS | 0.40 | 0.40 | 0.36 | 0.38 | 0.43 | 0.42 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 499.94M | 541.26M | 609.28M | 578.14M | 612.79M | 679.67M | 795.19M | 829.96M |
| Cash & ST investments | 280.37M | 321.40M | 402.82M | 314.77M | 297.70M | 290.83M | 340.58M | 328.37M |
| Inventory | -- | -- | -- | -- | -- | -- | -- | -- |
| Total assets | 1.06B | 1.18B | 1.25B | 1.28B | 1.35B | 1.44B | 1.62B | 1.70B |
| Total current liabilities | 155.10M | 229.35M | 221.08M | 495.69M | 277.95M | 326.40M | 290.12M | 324.13M |
| Short-term debt | 21.65M | 65.27M | 44.12M | 278.64M | 44.98M | 77.78M | 21.38M | 21.74M |
| Long-term debt | 263.24M | 194.13M | 201.96M | -- | 220.00M | 135.00M | 283.60M | 293.71M |
| Total liabilities | 443,617,000.00 | 513,087,000.00 | 528,685,000.00 | 589,748,000.00 | 587,940,000.00 | 552,535,000.00 | 688,541,000.00 | 789,530,000.00 |
| Total equity | 618.32M | 670.00M | 719.17M | 693.16M | 758.18M | 889.44M | 929.86M | 912.71M |
| Retained earnings | 484.24M | 551.90M | 641.38M | 756.14M | 899.11M | 1.08B | 1.28B | 1.53B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 831.31M | 858.32M | 891.95M | 829.96M | 797.36M | 875.28M |
| Cash & ST investments | 331.42M | 353.29M | 390.14M | 328.37M | 253.76M | 283.82M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 1.68B | 1.71B | 1.73B | 1.70B | 1.68B | 1.75B |
| Total current liabilities | 243.65M | 272.30M | 307.00M | 324.13M | 299.51M | 703.65M |
| Short-term debt | 22.31M | 23.26M | 24.06M | 21.74M | 21.81M | 399.89M |
| Long-term debt | 302.38M | 255.16M | 349.93M | 293.71M | 412.49M | -- |
| Total liabilities | 664,534,000.00 | 647,553,000.00 | 781,243,000.00 | 789,530,000.00 | 897,575,000.00 | 881,645,000.00 |
| Total equity | 1.01B | 1.06B | 952.39M | 912.71M | 778.80M | 866.24M |
| Retained earnings | 1.35B | 1.41B | 1.47B | 1.53B | 1.60B | 1.66B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 92.44M | 168.42M | 202.97M | 184.39M | 166.14M | 211.20M | 268.53M | 350.72M |
| Depreciation & amortization | 48.72M | 79.53M | 77.66M | 75.46M | 77.89M | 70.47M | 76.99M | 83.89M |
| Free cash flow | 51.65M | 127.88M | 160.75M | 147.14M | 121.31M | 158.40M | 222.26M | 298.12M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -43.11M | -41.36M | -79.95M | -118.36M | -71.58M | -126.28M | -202.90M | -322.25M |
| Ending cash balance | 104.13M | 127.04M | 225.52M | 143.81M | 125.62M | 145.40M | 171.40M | 165.97M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 3.24M | 109.38M | 120.72M | 117.38M | 1.72M | 87.89M |
| Depreciation & amortization | 19.60M | 8.09M | 33.58M | 22.62M | 20.90M | 7.57M |
| Free cash flow | -9.70M | 94.95M | 106.36M | 106.51M | -11.21M | 73.39M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -15.23M | -40.58M | -158.01M | -108.44M | -163.20M | -19.78M |
| Ending cash balance | 158.48M | 170.53M | 179.83M | 165.97M | 164.78M | 146.77M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 9.32 | 10.51 | 12.88 | 16.25 | 19.70 | 22.40 | 21.80 | 27.25 |
| ROA %i | 6.01 | 6.03 | 7.36 | 9.07 | 10.88 | 13.24 | 12.96 | 15.12 |
| ROIC %i | 7.90 | 8.05 | 9.36 | 11.34 | 13.75 | 16.89 | 16.73 | 19.71 |
| 5-year avg ROE %i | 10.05 | 10.50 | 10.74 | 11.52 | 13.73 | 16.35 | 18.61 | 21.48 |
| EBIT margin %i | 7.65 | 9.76 | 13.20 | 13.73 | 14.05 | 15.40 | 15.26 | 15.93 |
| FCF / sales %i | 5.89 | 12.94 | 16.77 | 13.11 | 8.59 | 9.71 | 12.09 | 14.28 |
| Current ratioi | 3.22 | 2.36 | 2.76 | 1.17 | 2.20 | 2.08 | 2.74 | 2.56 |
| Quick ratioi | 2.97 | 2.21 | 2.57 | 1.07 | 2.06 | 1.90 | 2.41 | 2.22 |
| Debt / assetsi | 26.86 | 28.28 | 26.54 | 27.08 | 23.26 | 18.79 | 22.54 | 23.71 |
| LT debt / equityi | 42.64 | 40.19 | 39.92 | 9.92 | 35.37 | 21.72 | 36.94 | 41.84 |
| Interest coveragei | 9.35 | 7.10 | 11.31 | 20.38 | 24.04 | 19.05 | 14.57 | 18.89 |
| Revenue CAGR (3Y) %i | 12.01 | 13.06 | 7.93 | 8.32 | 12.51 | 19.38 | 17.88 | 13.92 |
| Net income CAGR (3Y) %i | 3.23 | 3.10 | 22.32 | 26.47 | 28.32 | 27.29 | 20.00 | 20.64 |
| FCF CAGR (3Y) %i | -10.11 | 18.66 | 27.26 | 41.76 | -1.74 | -0.49 | 14.74 | 34.95 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | 23.81 | 24.70 | 25.96 | 27.25 | 28.09 | 25.94 |
| ROA %i | 13.87 | 14.71 | 14.44 | 15.12 | 15.00 | 14.47 |
| ROIC %i | 17.08 | 18.20 | 18.24 | 19.71 | 19.17 | 18.69 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 15.72 | 16.41 | 16.22 | 15.93 | 15.93 | 15.36 |
| FCF / sales %i | 12.91 | 14.11 | 14.16 | 14.28 | 13.75 | 12.29 |
| Current ratioi | 3.41 | 3.15 | 2.91 | 2.56 | 2.66 | 1.24 |
| Quick ratioi | 3.01 | 2.75 | 2.57 | 2.22 | 2.30 | 1.11 |
| Debt / assetsi | 23.03 | 19.95 | 25.06 | 23.71 | 30.93 | 27.92 |
| LT debt / equityi | 35.95 | 29.93 | 43.09 | 41.84 | 63.79 | 10.17 |
| Interest coveragei | 14.87 | 16.95 | 17.80 | 18.89 | 19.73 | 18.88 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Diversified
- Insurance is the largest reported line at 33.25% of revenue, across 4 reported segments.
- No single line clears half of revenue; Healthcare and Life Sciences is next at 26.56%, spreading the business across more than one real driver.
Revenue breakdown most recent period
Business
Insurance33.25%
Healthcare and Life Sciences26.56%
Banking, Capital Markets and Diversified Industries22.51%
International Growth Markets17.68%
Quote time 2026-10-07 20:02:45 · For reference only, not investment advice and not tailored to your situation.